Company / R&D Expense
ResMed R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$331.3M
FY2025
5-year range
$225.3M / $331.3M
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#23 of 105
Health Care
What the data says
ResMed's r&d expense of $331M is higher than 78% of companies in the Health Care sector (FY2025). R&D Expense has increased for 9 consecutive years, from $119M in FY2016 to $331M in FY2025.
Based on SEC 10-K filings.
$331M in FY2025 with a 5-year CAGR of +10.4%. Top quartile in the Health Care sector.
Improved from $288M to $331M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +9.3%
- 5-Year CAGR
- +10.4%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 105This company $331.3M Sector average $284.2M
▼
+16.6% above sector average
Key checks
Key Insights
- ResMed's r&d expense has grown for 9 consecutive years.
- 5-year CAGR of +10.4%, indicating consistent growth.
- In FY2025, r&d expense increased 7.7% year-over-year.
- Ranks #23 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $331.3M | +7.7% |
| FY2024 | $307.5M | +6.9% |
| FY2023 | $287.6M | +13.4% |
| FY2022 | $253.6M | +12.6% |
| FY2021 | $225.3M | +11.6% |
| FY2020 | $201.9M | +11.8% |
| FY2019 | $180.7M | +16.4% |
| FY2018 | $155.1M | +7.4% |
| FY2017 | $144.5M | +21.8% |
| FY2016 | $118.7M | +3.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026